ATE380884T1 - Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind. - Google Patents

Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind.

Info

Publication number
ATE380884T1
ATE380884T1 AT02704147T AT02704147T ATE380884T1 AT E380884 T1 ATE380884 T1 AT E380884T1 AT 02704147 T AT02704147 T AT 02704147T AT 02704147 T AT02704147 T AT 02704147T AT E380884 T1 ATE380884 T1 AT E380884T1
Authority
AT
Austria
Prior art keywords
apolipoprotein
gene
patient
mirtazapine
major depression
Prior art date
Application number
AT02704147T
Other languages
English (en)
Inventor
Greer Murphy
Alan Schatzberg
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/780,512 external-priority patent/US6399310B1/en
Priority claimed from US10/010,087 external-priority patent/US20030105082A1/en
Application filed by Organon Nv filed Critical Organon Nv
Application granted granted Critical
Publication of ATE380884T1 publication Critical patent/ATE380884T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Seasonings (AREA)
AT02704147T 2001-02-12 2002-02-12 Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind. ATE380884T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/780,512 US6399310B1 (en) 2001-02-12 2001-02-12 Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US10/010,087 US20030105082A1 (en) 2001-12-03 2001-12-03 Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4

Publications (1)

Publication Number Publication Date
ATE380884T1 true ATE380884T1 (de) 2007-12-15

Family

ID=26680764

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02704147T ATE380884T1 (de) 2001-02-12 2002-02-12 Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind.

Country Status (8)

Country Link
US (1) US20040106124A1 (de)
EP (1) EP1442133B1 (de)
JP (1) JP2004532190A (de)
AT (1) ATE380884T1 (de)
AU (1) AU2002237847A1 (de)
DE (1) DE60224078T2 (de)
ES (1) ES2296893T3 (de)
WO (1) WO2002064735A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092380A2 (en) * 2006-02-06 2007-08-16 Berkeley Heartlab, Inc. Apolipoprotein e genotyping and accompanying internet-based health management system
US10603272B2 (en) 2015-02-27 2020-03-31 Kindred Biosciences, Inc. Stimulation of appetite and treatment of anorexia in dogs and cats

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
US4515792A (en) * 1982-09-30 1985-05-07 Ciba-Geigy Corporation Tetracyclic heterocycles and antidepressant compositions thereof
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
ES2062310T3 (es) * 1989-12-06 1994-12-16 Akzo Nv Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.
ATE262592T1 (de) * 1992-10-13 2004-04-15 Univ Duke Verfahren zum nachweis der alzheimer krankheit
GB9408465D0 (en) * 1994-04-27 1994-06-22 Univ Mcgill Apolipoprotein e polymorphism & treatment of alzheimer's disease
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
ZA982368B (en) * 1997-03-27 1998-09-23 Akzo Nobel Nv New therapeutic combinations
ZA985765B (en) * 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
WO1999014367A1 (en) * 1997-09-12 1999-03-25 Bristol-Myers Squibb Company Method for determining propensity for developing late-onset alzheimer's disease
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
US6063573A (en) * 1998-01-27 2000-05-16 Clinical Micro Sensors, Inc. Cycling probe technology using electron transfer detection
ATE254918T1 (de) * 1998-04-02 2003-12-15 Akzo Nobel Nv Orale flüssige lösung enthaltend das antidepressivum mirtazapine

Also Published As

Publication number Publication date
JP2004532190A (ja) 2004-10-21
EP1442133B1 (de) 2007-12-12
AU2002237847A1 (en) 2002-08-28
US20040106124A1 (en) 2004-06-03
ES2296893T3 (es) 2008-05-01
WO2002064735A2 (en) 2002-08-22
DE60224078T2 (de) 2008-12-04
DE60224078D1 (de) 2008-01-24
WO2002064735A3 (en) 2004-05-13
EP1442133A4 (de) 2005-01-05
EP1442133A2 (de) 2004-08-04

Similar Documents

Publication Publication Date Title
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE348808T1 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
HUP0102511A2 (hu) Kombinált gyógykezelés bipoláris betegségek kezelésére
MY151032A (en) Treatment of tnf? related disorders
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
UA82828C2 (en) The use of enantiomeric pure escitalopram for treatment of depression
DE60320770D1 (de) Verfahren zur verabreichung von buprenorphin zur behandlung von depression
ATE447426T1 (de) Elektromagnetische stimulation bei patienten mit osteoporose
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
ATE380884T1 (de) Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind.
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
ATE544453T1 (de) Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE60013636D1 (de) Verfahren zur behandlung endzünlicher darmerkrankungen durch verwendung von choleratoxin untereinheit b
DE602004015321D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
DE69915849D1 (de) Verwendung von gnrh analogen zur behandlung von schizophrenie
HK1077306A1 (en) Ocular gene therapy
DE60002172T2 (de) Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)-2-cyclopenten-1-methanol in hbv
DE60213968D1 (de) Blutgerinnungsfaktor xiii zur behandlung von plättchenfunktionsstörungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties